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Abstract
Pericardial effusion can dangerously precipitate patient’s hemodynamic stability and requires prompt intervention in case 
of tamponade. We investigated potential predictors of in-hospital mortality, a composite outcome of in-hospital mortality, 
pericardiocentesis-related complications, and the need for emergency cardiac surgery and all-cause mortality in patients 
undergoing percutaneous pericardiocentesis. This is an observational, retrospective, single-center study on patients undergo-
ing percutaneous pericardiocentesis (2010–2019). We enrolled 81 consecutive patients. Median age was 71.4 years (inter-
quartile range [IQR] 58.1–78.1 years) and 51 (63%) were male. Most of the pericardiocentesis were performed in an urgency 
setting (76.5%) for cardiac tamponade (77.8%). The most common etiology was idiopathic (33.3%) followed by neoplastic 
(22.2%). In-hospital mortality was 14.8% while mortality during follow-up (mean 17.1 months) was 44.4%. Only hemody-
namic instability (i.e., cardiogenic shock, hypotension refractory to fluid challenge therapy and inotropes) was associated 
with in-hospital mortality at the univariate analysis (odds ratio [OR] 7.2; 95% confidence interval [CI] 1.76–29.4). Non-
neoplastic/non-idiopathic etiology and hemodynamic instability were associated with the composite outcome of in-hospital 
mortality, need for emergency cardiac surgery, or pericardiocentesis-related complications (OR 5.75, 95% CI 1.65–20.01, 
and OR 5.81, 95% CI 2.11–15.97, respectively). Multivariate Cox regression analysis adjusted for possible confounding 
variables (age, coronary artery disease, and hemodynamic instability) showed that neoplastic etiology was independently 
associated with medium-term mortality (hazard ratio [HR] 4.05, 95% CI 1.45–11.36). In a real-world population treated 
with pericardiocentesis for pericardial effusion, in-hospital adverse outcomes and medium-term mortality are consistent, in 
particular for patients presenting with hemodynamic instability or neoplastic pericardial effusion.
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Introduction
Pericardial effusion is a clinical condition characterized by 
an abnormal accumulation of fluid in the pericardial space. 
Given the limited space in the pericardial cavity, fluid accu-
mulation can severely impact patients’ hemodynamic status 
with dramatic clinical consequences. Multiple different eti-
ologies can be recognized including iatrogenic, infective, 
neoplastic, autoimmune, idiopathic, and several others less 
represented (e.g., congestive heart failure, uremic, liver cir-
rhosis, aortic syndromes) [1–10]. Regardless of the etiology, 
pericardial effusion is usually treated by percutaneous peri-
cardiocentesis, which has a twofold purpose, therapeutic and 
diagnostic [11]. The procedure can be performed both in the 
urgency/emergency clinical setting (i.e., cardiac tamponade) 
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or it can be programmed when the instrumental findings 
(echocardiography, cardiac tomography [CT] scan or mag-
netic resonance imaging [MRI]) and clinical characteristics 
of the patient suggest the possibility of an evolution towards 
cardiac tamponade [12, 13]. In clinical practice, chemi-
cal–physical examination, cytology and microbiology tests 
are essential steps in the diagnostic process aimed at delin-
eating the exact etiology of pericardial effusion [14–17]. 
It has been reported that neoplastic etiology is associated 
with higher mortality compared to the others [18]. How-
ever, given the great heterogeneity of patients included in 
the studies, it is not easy to identify potential predictors of 
mortality, and data available in the literature are scanty.
The aim of our study is to investigate the clinical charac-
teristics of patients undergoing percutaneous pericardiocen-
tesis and to evaluate possible predictors of adverse clinical 
outcomes and medium-term mortality according to different 
etiologies of pericardial effusion.
Methods
We performed an observational, retrospective, single-center 
study. All patients undergoing percutaneous pericardio-
centesis between January 2010 and December 2019 at the 
University Hospital of Modena were included in the study. 
The study protocol (No. 0007514/20) was approved by the 
local IRB/Ethics Committee in compliance with national 
regulations.
Patient and pericardial effusion analysis
Baseline and follow-up data were obtained from electronic 
and paper medical records and were stored in a customized 
database. Patients’ data were obtained through the review 
of electronic medical records. We retrospectively collected 
the following variables: age, sex, full clinical and medica-
tion history, etiological diagnosis of the pericardial effusion, 
clinical presentation features (cardiac tamponade, urgency/
emergency, hemodynamic instability, and atrial fibrillation), 
date of the pericardiocentesis, need for acute intra-hospital 
surgery, pericardiocentesis-related complications, puncture 
site, date of death and date of last clinical contact. All the 
patients underwent percutaneous pericardiocentesis, guided 
by echocardiography and/or fluoroscopy and had extended 
pericardial drainage until there was less than 50 ml of fluid 
remaining.
For the purpose of this analysis, the study population was 
divided into three groups according to different etiologies 
of pericardial effusion: (1) neoplastic, (2) idiopathic and (3) 
all other etiologies. The etiology of pericardial effusion was 
classified as follows: (i) neoplastic effusion was diagnosed 
if pericardial fluid cytology included atypical/malignant 
cells or negative cytological analysis with instrumental (CT 
scan and/or MRI) evidence of pericardial involvement with 
known or newly diagnosed neoplasia; (ii) iatrogenic effu-
sion if patients have undergone invasive medical tests or 
maneuvers that have caused pericardial effusion (e.g., coro-
nary intervention, pacemaker implantation, valvuloplasty), 
or patients with proven overdosed anticoagulation therapy, 
causing hemopericardium; (iii) acute myocardial infarc-
tion (AMI) mechanical complications included patients 
with diagnosis of acute–subacute myocardial infarction and 
mechanical complications such as myocardial wall rupture, 
(iv) pericardial effusion secondary to acute aortic syndrome 
included patients with diagnosis of aortic dissection, proven 
by transthoracic or transesophageal echocardiogram or CT 
angiography, causing hemopericardium, (v) infective effu-
sion included patients who had positive pericardial fluid cul-
ture for bacterial, mycobacterial or positive serological tests 
for viral etiology, (vi) autoimmune disease was considered 
in patients with signs of inflammation in a clinical setting of 
polyserositis, in known or newly diagnosed autoimmune dis-
ease, (vii) uremic pericardial effusion was diagnosed when 
blood urea nitrogen was > 60 mg/dl or the patient was dialy-
sis dependent in the absence of other identifiable causes, 
(viii) congestive heart failure group included patients with 
pericardial effusion in the presence of clinical symptoms 
and reduced left ventricular ejection fraction (LVEF) < 50%, 
if any other causes were excluded, ix) liver cirrhosis was 
considered in those patients diagnosed with decompensated 
liver cirrhosis, transudative pericardial fluid and after the 
exclusion of other possible causes, and (x) idiopathic etiol-
ogy was diagnosed when all the other possible diagnosis 
were excluded. Hemodynamic instability was defined as: 
cardiac arrest, systolic blood pressure (BP) < 90 mmHg or 
vasopressors required to achieve a BP ≥ 90 mmHg despite 
adequate filling status and end-organ hypoperfusion or sys-
tolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting 
longer than 15 min and not caused by new-onset arrhythmia, 
hypovolemia, or sepsis [19]. Cardiac tamponade was diag-
nosed in the presence of typical clinical and echocardio-
graphic signs or CT/MRI imaging. An estimated glomerular 
filtration rate (eGRF) < 60 ml/min/1.73  m2 identified patients 
with chronic kidney disease (CKD) according to the “Kidney 
Disease: Improving Global Outcome (KDIGO)” classifica-
tion [20]. Acute surgery included patients who underwent a 
surgical intervention after percutaneous pericardiocentesis, 
as definitive treatment (e.g., myocardial wall rupture surgical 
repair or pericardial window).
Study outcomes
The primary outcome of the study was all-cause mortal-
ity. Other outcomes of interest were in-hospital mortal-
ity and the composite outcome of in-hospital mortality, 
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need for emergency cardiac surgery or pericardiocentesis-
related complications.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation or median with interquartile range (IQR) for 
skewed distributions. Among-group comparisons were 
made using a non-parametric test (Kruskal–Wallis test). 
Categorical variables are expressed as counts and per-
centages. Between-group comparisons were made using a 
Chi-square test or a Fisher’s exact test if any expected cell 
count was less than five. Prognostic factors for in-hospital 
mortality and for the composite outcome were assessed by 
logistic univariate regression analysis. Medium-term sur-
vival curves were built using the Kaplan–Meier method. 
Comparisons were made using the log-rank test. A mul-
tivariate Cox proportional hazards regression analysis 
adjusted for age, hemodynamic instability and presence 
of coronary artery disease was performed to evaluate the 
effect of different pericardial effusion’s etiologies on all-
cause death during follow-up. In the comparison between 
etiologies, the idiopathic category (group 1) was used as 
the reference. In all analyses, a P value < 0.05 was con-
sidered statistically significant. Statistical analysis was 
performed using  SPSS® (version 26).
Results
Eighty-one consecutive patients who underwent pericar-
diocentesis between January 2010 and December 2019 
were included in this analysis. Patient clinical character-
istics stratified by three different etiological groups are 
shown in Table 1. Overall, median age was 71.4 years (IQR 
58.1–78.1 years) and 51/81 (63%) patients were male. Neo-
plastic etiology group was younger (p = 0.05) and tended to 
be characterized by a lower prevalence of comorbidities, in 
particular the absence of concomitant coronary artery dis-
ease (p = 0.004). No differences were found in antithrom-
botic treatment among different groups. Most of the pro-
cedures were performed in an urgency/emergency setting 
(76.5%) and the main indication was cardiac tamponade 
(77.8%). Hemodynamic instability at admission was signifi-
cantly lower in the idiopathic group (p < 0.001). Different 
etiologies of pericardial effusion are specified in Table 2. 
The most common etiology was idiopathic (33.3%) followed 
by neoplastic (22.2%) and iatrogenic (18.5%). Lung cancer 
was the most represented etiology in the neoplastic subgroup 
(50%). Among the iatrogenic group, 8 (53.3%) patients had 
coronary perforation during percutaneous coronary inter-
ventions and 2 (13.3%) patients experienced anticoagulant 
overdose. 
Major adverse events are shown in Table 3. During a 
mean follow-up of 17.1 ± 26.5 months, 36 (44.4%) patients 
died. The neoplastic group showed a significantly higher 
mortality rate compared to other groups (p < 0.001). 
Table 1  Baseline patients’ characteristics stratified by different etiologies
CKD chronic kidney disease, IQR interquartile range, LMWH low-molecular-weight heparin, NOAC non-vitamin K oral anticoagulants, VKA 
vitamin K antagonist
Total (N = 81) Neoplastic (N = 18) Idiopathic (N = 27) Others (N = 36) p value
Age, median [IQR] 71.4 [58.1–78.1] 66.7 [56.8–75.4] 66.8 [53.1–76.5] 76.1 [61.8–81.5] 0.05
Female, n (%) 30 (37.0) 7 (38.9) 8 (29.6) 15 (41.7) 0.64
Comorbidities, n (%)
Arterial hypertension 48 (60.8) 8 (47.1) 17 (63.0) 23 (65.7) 0.42
Dyslipidemia 28 (35.4) 4 (23.5) 11 (40.7) 13 (37.1) 0.49
Diabetes mellitus 17 (21.5) 1 (5.9) 5 (18.5) 11 (31.4) 0.11
Coronary artery disease 17 (21.5) 0 (0.0) 4 (14.8) 13 (37.1) 0.004
Atrial fibrillation 23 (28.4) 3 (16.7) 7 (25.9) 13 (36.1) 0.31
CKD 24 (30.8) 2 (12.5) 8 (29.6) 14 (40.0) 0.13
Antithrombotic treatment, n (%) 25 (30.9) 4 (22.2) 7 (25.9) 14 (38..8) 0.25
VKA 10 0 2 8
NOAC 6 0 3 3
LMWH or calcium heparin 9 4 2 3
Hemodynamic instability, n (%) 29 (36.3) 4 (22.2) 4 (14.8) 21 (60.0)  < 0.001
Urgency, n (%) 62 (76.5) 12 (66.7) 18 (66.7) 32 (88.9) 0.06
Cardiac tamponade, n (%) 63 (77.8) 12 (66.7) 20 (74.1) 31 (86.1) 0.23
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In-hospital mortality was 14.8% without any significant 
difference among groups. There were 5 (6.2%) major per-
icardiocentesis-related complications: 1 (1.25%) pleural 
puncture, 2 (2.5%) liver puncture with hemoperitoneum, 
1 (1.25%) right ventricle puncture with self-resolution and 
without effect on the quantity of pericardial fluid and 1 
(1.25%) infective complication treated with targeted anti-
biotic therapy. Fourteen out of 81 (17.3%) patients required 
emergency cardiac surgery. As shown in the Kaplan–Meier 
survival curve (Fig. 1), patients with malignant pericardial 
effusion’s etiology had a significantly worse prognosis at 
follow-up (log-rank test p = 0.001). At univariate logistic 
regression analysis (Table 4), only hemodynamic instabil-
ity was associated with in-hospital mortality (OR 7.20; CI 
1.76–29.40; p = 0.006). The etiology of pericardial effusion 
instead was not. With regard to the in-hospital compos-
ite outcome, hemodynamic instability (OR 5.81, 95% CI 
2.11–15.97, p = 0.001) and non-idiopathic/non-neoplastic 
group (OR 5.75, 95% CI 1.65–20.01, p = 0.006) were asso-
ciated with worse outcome (Table 4). At multivariate Cox 
proportional hazards regression analysis adjusted for age, 
hemodynamic instability and the presence of coronary artery 
disease, neoplastic etiology was independently associated 
with a higher risk of all-cause death during follow-up (HR 
4.05, 95% CI 1.45–11.36, p = 0.008) (Table 5).   
Discussion
Percutaneous pericardiocentesis is the procedure of choice 
for the removal of severe pericardial effusion presenting 
with or without cardiac tamponade. This procedure plays an 
important role for both diagnostic and therapeutic purposes 
[21, 22]. The present study analyzes a real-world popula-
tion undergoing pericardiocentesis and aims at improving 
patients’ clinical management, according to their specific 
pericardial effusion’s etiology, and defining predictors of 
worse clinical outcomes. The major findings of this analy-
sis are the following: first, percutaneous pericardiocentesis 
is fairly safe showing complications in a limited number 
of patients; second, hemodynamic instability is a predic-
tor of in-hospital mortality; third, patients presenting with 
pericardial effusion unrelated to neoplastic etiology were 
associated with a higher rate of in-hospital mortality, need 
for emergency cardiac surgery or pericardiocentesis-related 
complications; fourth, neoplastic etiology was independently 
associated with a higher risk of all-cause death during the 
follow-up. Nowadays, percutaneous pericardiocentesis is a 
safe procedure albeit it is not easy to perform. The most 
feared complications are ventricle, liver or pulmonary punc-
ture. To reduce the rate of these unwished events, the use of 
echo- or fluoroscopy-guided technique to better perform the 
procedure is recommended. In our study, peri-procedural 
complications occurred in a limited number of patients 
(6.2%). This result is in line with European data, (4–10%) 
and with the largest studies (5.9%) [3]. The diagnostic phase 
Table 2  Etiologies of pericardial effusion at admission
AMI acute myocardial infarction, PM pacemaker
















Temporary PM removal 1
Anticoagulant therapy overdose 2
Percutaneous interatrial defect closure 1
AMI complications 6 (7.4)
Infective 4 (4.9)
Acute heart failure 4 (4.9)
Autoimmune 3 (3.7)
Uremia 1 (1.2)
Liver cirrhosis 1 (1.2)
Aortic dissection 1 (1.2)
Others 1 (1.2)
Table 3  Major adverse events 
stratified by different etiologies
Total (N = 81) Neoplastic (N = 18) Idiopathic (N = 27) Others (N = 36) p value
All-cause death 36 (44.4) 14 (77.8) 6 (22.2) 16 (44.4) 0.001
In-hospital mortality 12 (14.8) 3 (16.7) 2 (7.4) 7 (19.4) 0.40
Major complications 5 (6.2) 0 (0.0) 1 (3.7) 4 (11.1) 0.29
Need of emergency 
cardiac surgery
14 (17.3) 3 (16.7) 2 (7.4) 9 (25.0) 0.19
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is certainly the most challenging when managing patients 
with pericardial effusion. This is due to incomplete or 
insufficient diagnostic tests that do not always allow for the 
discovery of the real etiology of the effusion. Cases with 
idiopathic etiology are prevalent in our study, followed by 
those of neoplastic origin: this may be explained also by the 
fact that our institution includes the Provincial Oncological 
Reference Center. Other studies in the literature have shown 
a predominance of the neoplastic etiology [7]. However, 
it has to be underlined that may exist a perception about 
underestimating neoplastic effusions, suspecting that the 
cytology of the pericardial fluid is sometimes insufficient to 
confirm the diagnosis. For this reason, the question arises 
as to whether pericardial biopsy must be carried out in case 
of strong suspicion [7]. This scenario is in line with our 
data but the lesser number of patients observed may have 
aggravated this aspect.
Regarding outcomes, we predictably have observed that 
hemodynamic instability increases the risk of intra-hospital 
mortality rate regardless of the etiology of the pericardial 
effusion; the higher intra-hospital mortality rate is probably 
a consequence of the fact that patients with acute heart con-
ditions often come to hospital and therefore must undergo an 
emergency life-saving procedure, which inevitably increases 
the patient’s clinical risk.
The in-hospital mortality rate that emerged in our case 
series is, however, comparable with that of other studies 
published in the literature (14–19%) [3, 7, 8, 23–25]. Orbach 
et al. [8] found that in-hospital mortality rate increases in the 
group of patients with pericardial effusion secondary to AMI 
mechanical complications and coagulopathies/ongoing anti-
coagulant treatment; this evidence was not observed in our 
study due to the scarce amount of events of this type (respec-
tively, 6 cases of AMI complications and 2 cases of hemo-
pericardium caused by anticoagulant treatment). In particu-
lar, pericardial effusion secondary to anticoagulant therapy 
is a clinical condition that has to be considered nowadays, 
with the extensive use of NOACs in the older population, 
mainly prescribed for atrial fibrillation [26, 27]. The group 
of patients presenting with pericardial effusion unrelated 
Fig. 1  Kaplan Meier curves for freedom from all-cause mortality
Table 4  Logistic regression 
analysis for predictors of 
in-hospital mortality and 
in-hospital composite outcome 
(in-hospital mortality, need 
of emergency cardiac surgery 
or pericardiocentesis-related 
complications)
* Analysis presented is unadjusted univariate logistic regression analysis; OR = odds ratio; CI confidence 
interval
In-hospital mortality* Composite outcome*
OR 95% CI P value OR 95% CI P value
Etiology
Idiopathic (reference) – – – – – –
Others 3.01 0.57–15.86 0.19 5.75 1.65–20.01 0.006
Neoplastic 2.50 0.37–16.72 0.34 2.21 0.50–9.72 0.29
Age 1.05 0.99–1.12 0.07 0.99 0.96–1.03 0.97
Female sex 0.83 0.23–3.02 0.77 0.79 0.29–2.07 0.63
Hypertension 2.15 0.53–8.68 0.28 0.91 0.35–2.35 0.84
Dyslipidemia 1.36 0.39–4.79 0.62 0.67 0.25–1.83 0.44
Diabetes mellitus 1.26 0.30–5.29 0.75 1.47 0.49–4.43 0.49
Coronary artery disease 2.07 0.54–7.97 0.29 2.75 0.92–8.25 0.07
Atrial fibrillation 2.02 0.57–7.19 0.28 1.09 0.39–3.03 0.86
Chronic kidney disease 1.34 0.35–5.10 0.66 1.00 0.36–2.77 1.00
Antithrombotic treatment 1.63 0.47–5.74 0.45 0.48 0.16–1.40 0.18
Hemodynamic instability 7.20 1.76–29.40 0.006 5.81 2.11–15.97 0.001
Urgency 3.88 0.47–32.23 0.21 3.37 0.88–12.79 0.07
Cardiac tamponade 3.59 0.43–29.93 0.24 3.07 0.81–11.75 0.10
Subxiphoid puncture site 0.87 0.23–3.29 0.85 0.77 0.25–2.35 0.65
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to neoplastic etiology was composed of AMI mechanical 
complications and iatrogenic etiology: these patients are 
often burdened by older age, important comorbidities and 
poorer clinical status. Probably, these can be the reasons for 
the higher rate of in-hospital mortality, need for emergency 
cardiac surgery or pericardiocentesis-related complications 
that we observed in this subgroup of patients.
Patients with neoplastic effusion instead have a higher 
mortality rate during the follow-up. Often the pericardial 
effusion develops gradually in the context of advanced 
cancer, therefore, patients show less frequently signs and 
symptoms of acute cardiac tamponade, but their short/
medium-term prognosis is poorer because of the neoplastic 
pathology itself [28]. Due to the poor prognosis of patients 
with advanced malignancy and associated pericardial effu-
sion, the primary therapeutic goal in these patients should 
be the improvement of symptoms and quality of life. In this 
complex setting, a multidisciplinary team approach, includ-
ing cardiologists, oncologists, cardio-thoracic surgeons and 
palliative care physicians, is advisable and should be encour-
aged [29].
The current analysis did not cover the period of COVID-
19 pandemic, and therefore, did not take into account that 
pericardial effusion is one of the manifestations of COVID-
19, with the possibility of cardiac tamponade in the setting 
of a severe clinical course [30]. Future studies will have to 
consider also this etiology of pericardial effusions [30–33].
Limitations of the study
The present study has specific limitations that need to be 
addressed. First, our cohort represents a single-medical 
center experience with a small sample size, thus limiting the 
generalization of the results. As any retrospective study, the 
statistical power of the analysis is limited due to the absence 
of a prospective design and follow-up. The small number of 
patients did not allow us to investigate any possible differ-
ence in outcome among specific subtypes of malignancy. 
Moreover, prognostic factors for in-hospital mortality and 
for the composite outcome were assessed only by logistic 
univariate regression analysis limiting the power of the asso-
ciation. Cox regression model was adjusted only for age, 
hemodynamic instability and the presence of coronary artery 
disease to avoid possible overfitting with the small number 
of events.
Lastly, the relatively short follow-up period could have 
limited power to associate the different etiology groups with 
outcomes.
Conclusions
The most common etiology of pericardial effusion requiring 
percutaneous pericardiocentesis in our contemporary real-
world population is idiopathic, and the most common clini-
cal presentation is cardiac tamponade. In-hospital adverse 
outcomes and medium-term mortality are not negligible. 
Hemodynamic instability was associated with in-hospital 
mortality and non-neoplastic/non-idiopathic etiology and 
hemodynamic instability were associated with the compos-
ite outcome of in-hospital mortality, need for emergency 
cardiac surgery or pericardiocentesis-related complications. 
Finally, neoplastic etiology was associated with higher 
medium-term mortality.
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